Mustang Bio stock climbs 9% amid drug development update [Seeking Alpha]
Fortress Biotech, Inc. (FBIO)
Last fortress biotech, inc. earnings: 11/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
fortressbiotech.com
Company Research
Source: Seeking Alpha
The biotech company said it is collaborating with Fred Hutchinson Cancer Center on a proof-of-concept, investigator-sponsored Phase 1 study of MB-106 for autoimmune disorders. Mustang expects the study to be initiated in Q4. A CD20-targeted CAR-T cell therapy, MB-106 is currently in Phase 1/2 clinical trials for relapsed or refractory B-cell non-Hodgkin lymphomas, or NHL, and chronic lymphocytic leukemia. The company also intends to enroll its first patient in the second half of the year for a registrational study of the therapy in the treatment of Waldenstrom macroglobulinemia, a rare type of B-cell NHL. Mustang noted that scientists from Fred Hutchinson were involved in discoveries related to the product and may benefit financially from them in the future. Mustang was founded by Fortress Biotech ( FBIO Recommended For You More Trending News Recommended For You More Trending News About MBIO Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
FBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBIO alerts
High impacting Fortress Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
FBIO
News
- Congruence Therapeutics Appoints Frank Taffy as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Fortress Biotech, Inc. (NASDAQ: FBIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Fortress Biotech, Inc. (NASDAQ: FBIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire
FBIO
Earnings
- 11/14/23 - Beat
FBIO
Sec Filings
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- 4/5/24 - Form 424B3
- FBIO's page on the SEC website